Flow cytometric testing of susceptibilities of Mycobacterium avium to amikacin, ciprofloxacin, clarithromycin and rifabutin in 24 hours  R.M. Vena, E.L.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Á. Pascual, S. Ballesta, I. García, E.J. Perea 
Molecular evolution of Mycobacterium tuberculosis
Helicobacter pylori resistance to antibiotics in 2014 in France detected by phenotypic and genotypic methods  A. Ducournau, L. Bénéjat, E. Sifré, E. Bessède,
Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995–2001 
Gut bacterial microbiota and obesity
Approach to diagnosis of infective endocarditis
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America 
Herpes zoster in non-hospitalized children
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
A.K. Reddy, P. Garg, I. Kaur  Clinical Microbiology and Infection 
Mycobacterium avium ssp
Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995–2001 
R. Cantón  Clinical Microbiology and Infection 
Hydatid disease Clinical Microbiology and Infection
E. Cambau, M. Drancourt  Clinical Microbiology and Infection 
How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development  R. Bax  Clinical Microbiology.
W. Witte, B. Pasemann, C. Cuny  Clinical Microbiology and Infection 
How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach  D. Guillemot  Clinical Microbiology.
Serotypes, biotypes and antimicrobial susceptibilities of Haemophilus influenzae isolated from invasive disease in children in Casablanca  N. Moustaoui,
Vector control: a cornerstone in the malaria elimination campaign
C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins
Sofie Arens, Jan Verhaegen, Ludo Verbist 
Training for the infectious diseases speciality in Norway
Laboratory diagnosis and biosafety issues of biological warfare agents
Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium  M. Denton, M.J. Hall, N.J.
Gastrointestinal and respiratory Mycobacterium avium colonization and development of disseminated infection in HIV-positive patients  Giampietro Nardi,
Rapidly growing mycobacteria in Singapore, 2006–2011
Isolation rate, T-serotyping and susceptibility to antibiotics of Group A Streptococcus from pediatric infections in Athens*   M. Kanellopoulou, A. Makri,
Metagenomics and probiotics
Effect of antioxidants on the immune response of Helicobacter pylori
L. Arreaza, J.A. Vázquez  Clinical Microbiology and Infection 
Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin  King A. , Bathgate.
Laboratory diagnosis of Clostridium difficile disease
Recent developments in staphylococcal scalded skin syndrome
S8 – S47 and O50 – O440 Clinical Microbiology and Infection
A. Bryskier  Clinical Microbiology and Infection 
Brucella detection in blood: comparison of the BacT/Alert standard aerobic bottle, BacT/Alert FAN aerobic bottle and BacT/Alert enhanced FAN aerobic bottle.
J. Garau  Clinical Microbiology and Infection 
Single- and multistep selection study of the antipneumococcal activity of BMS compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin 
Community-acquired pneumonia: epidemiologic and clinical consideration
Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial 
Training in infectious diseases and tropical medicine in Britain
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida 
Fibronectin concentrations in catheter sepsis
Andrew M. Middleton, Maureen V. Chadwick, Harold Gaya 
Circulation of international clones of levofloxacin non-susceptible Streptococcus pneumoniae in Taiwan  Y.-C. Hsieh, L.-Y. Chang, Y.-C. Huang, H.-C. Lin,
Clinical infection services—the Leiden experience
C. Gagliotti, L. Nobilio, M.L. Moro 
An after-hours clinical liaison blood culture service—is it worth it?
Clinical Microbiology and Infection
Overview of cefixime use in community-acquired infections
K. Kaier, N.T. Mutters, U. Frank  Clinical Microbiology and Infection 
Clinical and molecular epidemiology of chromosome-mediated resistance to third- generation cephalosporins in Enterobacter isolates in eastern France  D.
Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe  Robert D. Fox  Clinical Microbiology.
Abstracts Clinical Microbiology and Infection
Modelling during an emergency: the 2009 H1N1 influenza pandemic
New oral cephalosporins in pediatric community-acquired infections
Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relation to ethnicity  R.J.L.F. Loffeld, C.A.P.M.J.
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group†   H. Goossens  Clinical.
J.L. Balcázar  Clinical Microbiology and Infection 
G.C. Schito  Clinical Microbiology and Infection 
Typing of Clostridium difficile
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
Pharmacokinetics of once-daily amikacin in pediatric patients
Localized Mycobacterium avium complex infection in a patient on HAART
The future of diagnostic bacteriology
Presentation transcript:

Flow cytometric testing of susceptibilities of Mycobacterium avium to amikacin, ciprofloxacin, clarithromycin and rifabutin in 24 hours  R.M. Vena, E.L. Munson, D.J. DeCoster, C.L. Croke, D.B. Fett, S.M. Callister, R.F. Schell  Clinical Microbiology and Infection  Volume 6, Issue 7, Pages 366-373 (July 2000) DOI: 10.1046/j.1469-0691.2000.00100.x Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Number of M. avium cells (events)/mL detected by flow cytometry with or without (▪) exposure to 0.01 (▴), 0.5 (•), 2.0 (⋄) or 8.0 (□) mg/L of amikacin (a), clarithromycin (b), ciprofloxacin (c), or rifabutin (d) for 24 or 48h. The experimental error was ±0.26, 0.24, 0.15 and 0.11 for amikacin (a), clarithromycin (b), ciprofloxacin (c), and rifabutin (d), respectively. Clinical Microbiology and Infection 2000 6, 366-373DOI: (10.1046/j.1469-0691.2000.00100.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Susceptibility index values of different isolates of M. avium (⋄=768, ▪=244, •=175 for (a); ⋄=825, ▪=510, •=141 for (b); ⋄=730, ▪=250, •=141 for (c); and ⋄=455, ▪=244, •=266 for (d), with or without exposure to selected concentrations of amikacin (a), clarithromycin (b), ciprofloxacin (c), or rifabutin (d) for 24h. Clinical Microbiology and Infection 2000 6, 366-373DOI: (10.1046/j.1469-0691.2000.00100.x) Copyright © 2000 European Society of Clinical Infectious Diseases Terms and Conditions